利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

120 条记录 (耗时 0.053 秒)

    Inhibition of Neovascularization by Cerium Oxide Nanoparticles
    85.
    发明申请
    Inhibition of Neovascularization by Cerium Oxide Nanoparticles 有权
    通过氧化铈纳米颗粒抑制新血管形成

    公开(公告)号：US20090269410A1

    公开(公告)日：2009-10-29

    申请号：US12429650

    申请日：2009-04-24

    申请人： James F. McGinnis ,  Lily L. Wong ,  Xiaohong Zhou

    发明人： James F. McGinnis ,  Lily L. Wong ,  Xiaohong Zhou

    IPC分类号： A61K33/24 ,  A61K9/14 ,  A61P29/00 ,  A61P27/02 ,  A61P9/00 ,  A61P19/02 ,  A61P1/00 ,  A61P17/00

    CPC分类号： A61K9/14 ,  A61K33/24

    摘要： The present invention provides methods for reducing, reversing or inhibiting neovascularization in a tissue of a mammalian subject having a pathological condition involving neovascularization by administration in vivo of nanoceria particles (cerium oxide nanoparticles) to the subject. The method of the invention is useful, for example, for reducing, treating, reversing or inhibiting neovascularization in ocular tissue such as the retina, macula or cornea; in skin; in synovial tissue; in intestinal tissue; or in bone. In addition, the method of the invention is useful for reducing or inhibiting neovascularization in a neoplasm (tumors), which can be benign or malignant and, where malignant, can be a metastatic neoplasm. As such, the invention provides compositions, which contain nanoceria particles and are useful for reducing, treating, reversing or inhibiting angiogenesis in a mammalian subject.

    摘要翻译： 本发明提供了通过在受试者体内施用纳米颗粒（氧化铈纳米颗粒）的体内，减少，逆转或抑制具有涉及新血管形成的病理状况的哺乳动物受试者的组织中的新生血管形成的方法。 本发明的方法例如用于减少，治疗，逆转或抑制眼组织如视网膜，黄斑或角膜中的新生血管形成; 在皮肤上 在滑膜组织中 在肠组织中 或在骨头。 此外，本发明的方法可用于减少或抑制肿瘤（肿瘤）中的新生血管形成，其可以是良性或恶性的，并且恶性肿瘤可以是转移性肿瘤。 因此，本发明提供了含有纳米颗粒并且可用于在哺乳动物受试者中减少，治疗，逆转或抑制血管生成的组合物。

    DISCRIMINATION OF SUPRAVENTRICULAR TACHYCARDIA FROM VENTRICULAR TACHYCARDIA
    86.
    发明申请
    DISCRIMINATION OF SUPRAVENTRICULAR TACHYCARDIA FROM VENTRICULAR TACHYCARDIA 审中-公开
    从室内TACHYCARDIA分离的非致病性TACHYCARDIA

    公开(公告)号：US20080269819A1

    公开(公告)日：2008-10-30

    申请号：US11740565

    申请日：2007-04-26

    申请人： Xiaohong Zhou

    发明人： Xiaohong Zhou

    IPC分类号： A61N1/365

    CPC分类号： A61N1/3622 ,  A61N1/36114 ,  A61N1/3962

    摘要： An implantable medical device and associated method discriminate between ventricular tachycardia and supraventricular tachycardia. Cardiac signals are sensed for detecting ventricular intervals corresponding to a tachycardia. Electrical stimulation pulses are delivered to cardiac neural tissue and verified as being effective in exciting the cardiac neural tissue. If the ventricular intervals corresponding to the tachycardia are increased in response to delivering stimulation pulses to the cardiac neural tissue, the tachycardia is detected as a supraventricular tachycardia.

    摘要翻译： 植入式医疗装置和相关方法区分室性心动过速和室上性心动过速。 感测心脏信号以检测对应于心动过速的心室间隔。 电刺激脉冲被递送到心脏神经组织并被证实是有效激励心脏神经组织。 如果对应于心动过速的心室间隔响应于向心脏神经组织递送刺激脉冲而增加，则将心动过速检测为室上性心动过速。

    METHOD AND APPARATUS FOR INDUCED T-WAVE ALTERNANS ASSESSMENT
    87.
    发明申请
    METHOD AND APPARATUS FOR INDUCED T-WAVE ALTERNANS ASSESSMENT 有权
    用于诱导T波变换器评估的方法和装置

    公开(公告)号：US20080082133A1

    公开(公告)日：2008-04-03

    申请号：US11536946

    申请日：2006-09-29

    申请人： Xiaohong Zhou

    发明人： Xiaohong Zhou

    IPC分类号： A61N1/00

    CPC分类号： A61B5/0456 ,  A61B5/0452 ,  A61N1/365 ,  G16H40/63

    摘要： An implantable medical device and associated method assesses T-wave alternans. The method includes sensing a cardiac signal from implanted electrodes subsequent to a premature contraction; measuring a T-wave parameter from the sensed cardiac signal for a plurality of cardiac cycles; and determining a T-wave alternans metric corresponding to the measured T-wave parameter.

    摘要翻译： 可植入医疗器械和相关方法评估T波交替。 该方法包括在过早收缩之后感测来自植入电极的心脏信号; 从感测的心脏信号中测量多个心动周期的T波参数; 以及确定对应于所测量的T波参数的T波交替量度。

    Delivery of a sympatholytic cardiovascular agent to the central nervous system to counter heart failure and pathologies associated with heart failure
    88.
    发明授权
    Delivery of a sympatholytic cardiovascular agent to the central nervous system to counter heart failure and pathologies associated with heart failure 有权
    向中枢神经系统递送交感神经心血管药物以对抗心力衰竭和与心力衰竭相关的病理

    公开(公告)号：US07232435B2

    公开(公告)日：2007-06-19

    申请号：US10773965

    申请日：2004-02-06

    申请人： Keith R. Hildebrand ,  Michael R. Ujhelyi ,  Xiaohong Zhou ,  Daniel C. Sigg ,  Linda M. Page

    发明人： Keith R. Hildebrand ,  Michael R. Ujhelyi ,  Xiaohong Zhou ,  Daniel C. Sigg ,  Linda M. Page

    IPC分类号： A61K9/22

    CPC分类号： A61M5/142 ,  A61M5/14276 ,  A61M5/1723 ,  A61M2005/14208 ,  A61M2205/3523 ,  A61M2230/00 ,  A61M2230/04 ,  A61M2230/63 ,  A61N1/3962

    摘要： A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms and otherwise treat heart failure (HF) and pathologies associated with HF. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with HF (or pathologies associated with HF) and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist, e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine.

    摘要翻译： 由药物输送泵递送至中枢神经系统部位的交感神经心血管药物以缓解症状，另外治疗与HF有关的心力衰竭（HF）和病理学。 药物输送泵可以是外部或植入式输液泵（IIP），其与延伸到现场的药物输注导管结合。 患者活化剂可以命令递送剂量和/或与传感器耦合的可植入心脏监测器（IHM）可以检测与HF相关的生理学参数（或与HF相关的病理学）和触发剂量递送。 IIP和IHM可以组合成单个可植入医疗设备（IMD），或者可以构成通过任何已知的通信机制进行通信的单独IMD。 交感神经心血管药物是由α-肾上腺素能激动剂和α2-肾上腺素能激动剂组成的组之一，例如可乐定，对氨基可乐定，胍苯胺，利脒，替扎尼定，莫西康定，甲基多巴，甲苯噻嗪，胍法辛， 右美托咪定。

    Neurostimulation to treat effects of sleep apnea
    89.
    发明授权
    Neurostimulation to treat effects of sleep apnea 有权
    神经刺激治疗睡眠呼吸暂停的效果

    公开(公告)号：US07155278B2

    公开(公告)日：2006-12-26

    申请号：US10419405

    申请日：2003-04-21

    申请人： Gary W. King ,  Marcus J. Mianulli ,  Michael R. S. Hill ,  Thomas J. Mullen ,  Roy L. Testerman ,  John E. Burnes ,  Xiaohong Zhou

    发明人： Gary W. King ,  Marcus J. Mianulli ,  Michael R. S. Hill ,  Thomas J. Mullen ,  Roy L. Testerman ,  John E. Burnes ,  Xiaohong Zhou

    IPC分类号： A61N1/36

    CPC分类号： A61N1/3601 ,  A61N1/36017 ,  A61N1/36114

    摘要： Neurostimulation is delivered to one or more predetermined locations on or within a patient in order to treat effects of sleep apnea by modulating autonomic nervous activity. Delivery of neurostimulation at predetermined locations can decrease sympathetic nervous activity and/or increase parasympathetic nervous activity, countering the increased intrinsic sympathetic activity associated with apnea-arousal cycles. In some embodiments, neurostimulation is delivered to the spinal cord of the patient via an implanted electrode. In other embodiments, neurostimulation is delivered transcutaneously to the spinal cord or other locations via electrodes located on the surface of the patient. In some embodiments, delivery of neurostimulation is initiated or modified in response to detection of apneas.

    摘要翻译： 神经刺激被递送到患者体内或患者内的一个或多个预定位置，以通过调节自主神经活动来治疗睡眠呼吸暂停的影响。 在预定位置递送神经刺激可降低交感神经活动和/或增加副交感神经活动，抵抗与呼吸暂停 - 觉醒周期相关的增加的内在交感神经活动。 在一些实施方案中，神经刺激经由植入的电极递送至患者的脊髓。 在其他实施方案中，神经刺激通过位于患者表面上的电极经皮递送至脊髓或其它位置。 在一些实施方案中，响应于呼吸暂停的检测开始或修饰神经刺激的递送。